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Background/Aims: Sept4, a subunit of the septin cytoskeleton speciﬁcally expressed in quiescent hepatic
stellate cells (HSCs), is downregulated through transdifferentiation to ﬁbrogenic and contractile myoﬁbro-
blastic cells. Since Sept4−/−mice are prone to liver ﬁbrosis, we aimed to identify the unknown molecular
network underlying liver ﬁbrosis by probing the association between loss of Sept4 and accelerated
transdifferentiation of HSCs. Methods: We compared the transcriptomes of Sept4+/+ and Sept4−/− HSCs
undergoing transdifferentiation by DNA microarray and quantitative reverse transcription polymerase chain
reaction (RT-PCR) analysis. Because Dickkopf2 (Dkk2) gene expression is reduced in Sept4−/− HSCs, we tested
whether supplementing Dkk2 could suppress myoﬁbroblastic transformation of Sept4−/− HSCs. We tested
the involvement of the canonical Wnt pathway in this process by using a lymphoid enhancer-binding factor/
transcription factor-luciferase reporter assay. Results: We observed consistent upregulation of Dkk2 in
primary cultured HSCs and in a carbon tetrachloride liver ﬁbrosis in mice, which was decreased in the absence
of Sept4. Supplementation with Dkk2 suppressed the induction of pro-ﬁbrotic genes (α-smooth muscle actin
and 2 collagen genes) and induced an anti-ﬁbrotic gene (Smad7) in Sept4−/− HSCs. In human liver specimens
with inﬂammation and ﬁbrosis, Dkk2 immunoreactivity appeared to be positively correlated with the degree
of ﬁbrotic changes. Conclusions: Pro-ﬁbrotic transformation of HSCs through the loss of Sept4 is, in part, due
to reduced expression of Dkk2 and its homologues, and the resulting disinhibition of the canonical Wnt
pathway.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Chronic liver inﬂammation caused by viral infections, alcohol and
other toxic chemicals, and metabolic disorders is accompanied by
tissue remodeling and ﬁbrosis. These interrelated pathologicaleverse transcription polymer-
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l rights reserved.processes are major issues in hepatology because they are implicated
in major clinical disorders, namely liver cirrhosis and carcinoma.
Previous studies have highlighted hepatic stellate cells (HSCs) as
pivotal players contributing to liver ﬁbrosis [1,2]. Upon liver damage,
HSCs transdifferentiate into myoﬁbroblastic cells by inﬂammatory
cytokines releasedmainly from Kupffer cells (KCs). Transformed HSCs
are distinct from quiescent HSCs in terms of their proliferative
activity, contractility facilitated by α-smooth muscle actin (α-SMA)
expression, and production of collagens and other extracellular
matrices. Since these properties contribute to the pathogenesis of
liver ﬁbrosis and cirrhosis, the molecular mechanism underlying
myoﬁbroblastic transformation of HSCs has been a research focus in
this ﬁeld.
Septins are a family of cytoskeletal/scaffold proteins ubiquitously
expressed in eukaryotic cells. Among the 13 septin genes shared by
mice and humans, Sept4 is unique in that it is expressed in speciﬁc
cells such as Bergmann glial cells in the cerebellum, dopamine
neurons in the midbrain, and spermatozoa. Loss of Sept4 causes
disparate phenotypes in these systems [3,4].
Table 1
Primers used quantitative reverse transcription polymerase chain reaction.
Primer Forward Reverse
α-Sma GTCCCAGACATCAGGGAGTAA TCGGATACTTCAGCGTCAGGA
18S AGTCCCTGCCCTTTGTACACA CGATCCGAGGGCCTCACTA
Col1α1 GCTCCTCTTAGGGGCCACT CCACGTCTCACCATTGGGG
Col3α1 CACCCTTCTTCATCCCACTC TCTCCAAATGGGATCTCTGG
Dkk1 CTCATCAATTCCAACGCGATCA GCCCTCATAGAGAACTCCCG
Dkk2 CTGATGCGGGTCAAGGATTCA CTCCCCTCCTAGAGAGGACTT
Dkk3 CTCGGGGGTATTTTGCTGTGT TCCTCCTGAGGGTAGTTGAGA
Smad7 GCATCTTCTGTCCCTGCTTC CCGGTCTTCCTTTCCTTTTC
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quiescent HSCs in the liver, it is strongly downregulated through
transdifferentiation of HSCs in vitro, and Sept4 protein is undetectable
in HSCs in human specimens with liver ﬁbrosis. Since Sept4−/− mice
are prone to liver ﬁbrosis, the presence of Sept4 contributes to the
suppression of myoﬁbroblastic transformation of HSCs by unknown
mechanisms [5]. In this study, we examined the accelerated
transdifferentiation of HSCs in Sept4−/− mice attempting to identify
the unknown molecular network underlying liver ﬁbrosis and the
physiological role of Sept4 in HSCs.
By comparing the transcriptomes of HSCs collected from Sept4+/+
and Sept4−/−mice, we found reproducible differences. Here, we focus
on Dickkopf2 (Dkk2) and its homologues. We found that Dkk2 is
expressed speciﬁcally in HSCs, that it is upregulated through
myoﬁbroblastic transformation in vivo and in vitro, and that the Dkk
upregulation is diminished in Sept4−/− HSCs. Previous studies from
other groups have shown that the canonical Wnt pathway promotes
ﬁbrosis of the liver, kidney, lung, and other tissues [6–9], which is
countered by Dkks that interfere with the interaction between Wnt
proteins, the cognate membrane-bound receptor Frizzled (Fzd), and
LRP5/6 (low-density lipoprotein receptor-related protein 5/6) [10–
12]. On the basis of the above information and our own data, we
conclude that pro-ﬁbrotic transformation of HSCs in the absence of
Sept4 is, at least in part, due to the reduced upregulation of Dkk genes
and the resulting disinhibition of the canonical Wnt pathway.
2. Materials and methods
2.1. Animals
Characterization of Sept4−/− mice with a C57BL/6 J background
has been reported previously [3–5]. The protocol for animal handling
was reviewed and approved by the Animal Care and Use Committee of
Kyoto University.
2.2. Liver cell fractionation and cell culture
We fractionated HSCs from Sept4+/+ or Sept4−/−male mice using
a standard method with some modiﬁcations [5,13]. In brief, we
dispersed liver cells by infusing 0.025% Pronase E (Kaken Pharma-
ceutical, Tokyo, Japan) and 0.025% collagenase (Wako, Osaka, Japan)
in SC-2 solution (137 mM NaCl, 5.4 mM KCl, 0.57 mM NaH2PO4,
0.85 mMNa2HPO4, 10 mMHEPES, 4.2 mMNaHCO3, and 3.8 mM CaCl2
[pH 7.25]). The collected liver cells were centrifuged on an 8.0%
Nycodenz (Nycomed Pharma, Oslo, Norway) cushion. The density-
separated HSCs were grown on uncoated dishes in Dulbecco's
Modiﬁed Eagle's Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) and antibiotics in 5% CO2 at 37 °C. The purity of
HSCs was consistently more than 98%, as assessed by the presence of
lipid droplets and autoﬂuorescence of vitamin A. We isolated
hepatocytes as previously described [14]. In brief, the liver cells
dispersed by infusing 0.03% collagenase in SC-2 solution were
centrifuged at 50 ×g for 1 min. The cell pellet was washed twice by
resuspending in GBSS-B solution (137 mM NaCl, 5.0 mM KCl, 1.0 mM
MgCl2, 0.28 mMMgSO4, 0.84 mMNaH2PO4, 0.22 mMKH2PO4, 5.5 mM
glucose, 2.7 mMNaHCO3, and 1.5 mM CaCl [pH 7.25]) and pelleting at
50 ×g for 1 min.We grew the fractionated hepatocytes using the same
method as for HSCs, except that the dishes were coated with type I
collagen.
2.3. Experimental liver ﬁbrosis induced by carbon tetrachloride
As previously reported [5], we injected carbon tetrachloride (CCl4)
(1.0 μl/g body weight, 25% [v/v] in olive oil) or vehicle alone
intraperitoneally into 6-week-old, male Sept4+/+ and Sept4−/−
mice, biweekly for 10 weeks.2.4. Total RNA extraction and DNA microarray analysis
We prepared total RNA from HSCs at the 3rd day in vitro (DIV3)
using a phenol–chloroform extraction method (TRIzol; Invitrogen,
Carlsbad, CA) and monitored the quality of total RNA from the
elution proﬁle of 18S and 28S ribosomal RNA [15] using the
Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA). We
ampliﬁed RNA (aRNA) samples using a T7-RNA polymerase system
(TargetAmp 1-Round Aminoallyl aRNA ampliﬁcation kit; Epicentre,
Madison, WI) and labeled the aRNA samples using Cy5 Mono-
Reactive Dye Pack (GE Healthcare, England). We hybridized DNA
microarray chips (3D-Gene Mouse Oligo chip 24 k; Toray, Tokyo,
Japan) with Cy-5-labeled aRNA samples at 37 °C for 16 h and then
washed the chips thoroughly. We scanned the hybridized chips and
acquired chip image data using ProScanArray (Perkin Elmer,
Waltham, MA). The scanned image data were processed using
Genepix Pro 4.0 software (Molecular Devices, Sunnyvale, CA) to
extract gene expression data, which were normalized using MATLAB
software (Mathworks, Natick, MA) and a quantile normalization
method [16]. For the above procedures, we followed the manufac-
turers' protocols with some modiﬁcations. We have registered the
microarray data with NCBI's Gene Expression Omnibus (GEO)
database under the accession number GSE24588.2.5. Quantitative reverse transcription polymerase chain reaction analysis
Total RNAwas extracted from liver samples or fractioned liver cells
using TRIzol and reverse transcribed into cDNA using Omniscript RT
Kit (QIAGEN, Germantown, MD) with random primers (Invitrogen).
We conducted quantitative reverse transcription polymerase chain
reaction (qRT-PCR) with gene-speciﬁc PCR primers (Table 1) and
SYBR Green I Master reaction mix on a LightCycler 480 II (Roche
Diagnostics, Basel, Switzerland). We quantiﬁed the relative abun-
dance of each gene product against 18S as internal controls with the
LightCycler 480 software (ver. 1.5).2.6. Immunoblot analysis
We homogenized and sonicated cells or tissues in lysis buffer
(50 mM Tris–HCl, 2% sodium dodecyl sulfate, and 10% glycerol), and
centrifuged the homogenates at 15,000 ×g for 10 min. After measur-
ing the protein concentration and adding bromophenol blue (ﬁnal
concentration, 0.1%) and 2-mercaptoethanol (5%), each sample was
separated by sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE), transferred onto a polyvinylidene ﬂuoride (PVDF)
membrane (Hybond-P, GE Healthcare), and probed with primary
antibodies (anti-Dkk2, anti-desmin, anti-FLAGM2; SIGMA-Aldrich, St.
Louis, MO; anti-albumin, BETHYL; Montgomery, TX, anti-PECAM-1,
anti-β-actin; Santa Cruz Biotechnology, Santa Cruz, CA). After
incubation with horseradish peroxidase-conjugated secondary anti-
bodies (Santa Cruz Biotechnology) and chemiluminescence reaction
Table 2A
Genes downregulated in Sept4−/− hepatic stellate cells (10 from the top).
Gene
symbol
Control
(Sept4+/+)
Sept4−/− Fold
change
Gene annotation
(Log2) (Log2)
1 Dkk2 4.79 0.820 0.0640 Dickkopf homolog 2
2 Ivl 6.22 2.93 0.102 Involucrin
3 Sept4 7.24 4.02 0.107 septin 4
4 Ptgs2 10.9 7.88 0.127 Prostaglandin-endoperoxide synthase
2
5 Acta1 6.04 3.06 0.127 Actin, alpha 1, skeletal muscle
6 Tll1 7.72 4.76 0.128 Tolloid-like
7 Kctd11 3.46 0.556 0.133 Potassium channel tetramerisation
domain containing 11
8 Sprrl9 5.72 2.82 0.135 Small proline rich-like 9
9 Ahrr 4.77 1.90 0.137 Aryl-hydrocarbon receptor repressor
10 Kcnj5 3.17 0.317 0.139 Potassium inwardly-rectifying
channel J5
Table 2B
Genes upregulated in Sept4−/− hepatic stellate cells (10 from the top).
Gene
symbol
Control
(Sept4+/+)
Sept4−/− Fold
change
Gene annotation
(Log2) (Log2)
1 Nfat5 0.838 4.60 13.5 Nuclear factor of activated
T-cells 5
2 Saa3 3.81 7.29 11.2 Serum amyloid A 3
3 Gm839 2.75 6.11 10.2 Gene model 839, (NCBI)
4 Cuedc1 4.99 8.26 9.70 CUE domain containing 1
5 Gpr160 3.29 6.52 9.38 G protein-coupled
receptor 160
6 Gpr103 0.113 3.30 9.12 G protein-coupled
receptor 103
7 Ntf3 0.886 4.05 8.98 Neurotrophin 3
8 Akp2 7.74 10.9 8.74 Alkaline phosphatase 2,
liver
9 Slc10a6 1.08 4.14 8.38 Solute carrier family 10,
member 6
10 Hsd3b2 1.05 4.02 7.85 Hydroxysteroid
dehydrogenase-2,
deltab5N−3-beta
Comparative DNA microarray data of Sept4−/− and Sept4+/+ hepatic stellate cells
(HSCs), showing representative genes whose expression were up- (A) and
downregulated (B) in Sept4−/− HSCs. All the data have been deposited to NCBI GEO
under an accession number of GSE24588.
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using an image analyzer, LAS-4000 (FujiFilm, Tokyo, Japan).
2.7. Construction of an expression plasmid for FLAG-Dkk2
We ampliﬁed the coding region of a mouse Dkk2 cDNA clone from
the FANTOM collection (RIKEN) by PCR with a set of oligonucleotide
primers, i.e., 5′-GAGAGAAGCTTTCACAGCTAGGCAGCTCG-3′ and 5′-
CGGGATCCTCAGATCTTCTGGCATAC-3′. The HindIII-BamHI-digested
fragmentwas inserted in-frame into the cognate sites of an expression
plasmid, pFLAG-CMV1, (SIGMA-Aldrich) and the DNA sequence was
conﬁrmed. The FLAG-tag of this vector is preceded by a signal
sequence for secretion and a signal peptidase cleavage site. We used
the empty pFLAG-CMV1 plasmid as a control.
2.8. LX-2 cell culture, transfection, and FLAG-Dkk2 conditioned medium
We cultured 5.0×105 LX-2 cells [17] (a generous gift from Dr.
Friedman and Dr. Ikeda) per 60-mm dish in DMEM supplemented
with 10% FBS. After about 24 h, we transfected the cells with the
FLAG-Dkk2 or empty plasmid using FuGENE6 (Roche Diagnostics).
We collected the culture supernatant (conditioned medium)
containing recombinant FLAG-Dkk2 or FLAG-tag ~72 h after
transfection.
2.9. Immunoprecipitation
We incubated the culture supernatant of the transfected LX-2 cells
with anti-FLAGM2 antibody (SIGMA-Aldrich), followed by adsorption
with Protein G Sepharose beads (GE Healthcare) for 2 h. After
washing the beads 3 times with TNE buffer (10 mM Tris–HCl at pH
7.8, 1% NP40, 0.15 M NaCl, and 1 mM EDTA), we subjected the
immunoprecipitates to immunoblot analysis as described above
(Section 2.6).
2.10. Luciferase assay
As described above (Section 2.8), we seeded 5.0×104 LX-2 cells
into each well of 12-well plates and co-transfected the cells with the
reporter plasmid TOP-Flash (Upstate; Millipore), which is designed to
monitor the Lef/Tcf-mediated transactivation of ﬁreﬂy luciferase
(emission, 556 nm) [18], and the pGL4.74 [hRluc/TK] vector (Promega,
Madison, WI) encoding Renilla luciferase (emission, 480 nm) to
evaluate the transfection efﬁciency. After 24 h, we added the
conditioned medium (ﬁnal concentration, N90%) containing FLAG-
taggedmouse Dkk2 or FLAG-tag alone, or recombinant Dkk2 (nominal
concentration, 5 μg/ml [184 nM]; R&D SYSTEMS, Inc., Minneapolis,
MN). At 48 h after addition of the conditioned medium, we measured
the activities of the 2 luciferases expressed in LX-2 cells using a Dual-
Luciferase Reporter Assay System (Promega) and a Fluoroskan Ascent
FL (Thermo Scientiﬁc, Waltham, MA), according to themanufacturers'
instructions. We normalized the data by dividing the luminescence of
the ﬁreﬂy luciferase by that of the Renilla luciferase. The experiments
were performed in triplicate.
2.11. Immunohistochemistry of human liver tissues
We procured human tissue specimens of livers afﬂicted with
chronic hepatitis, liver ﬁbrosis, or liver cirrhosis from the Department
of Surgery, Kyoto University Hospital. All samples were obtained with
the patients' informed consent. We immunostained parafﬁn sections
with anti-Dkk2 antibody (Abcam, Cambridge, UK) as described
previously [5,14] and observed them under a digital microscope
(BZ-9000; KEYENCE, Japan).2.12. Statistical analysis
Quantitative data are expressed as mean±SEM. For statistical
analysis, we used Mann–Whitney's U test and a general linear model
with repeated measures.
3. Results
3.1. Comparative transcriptome analysis revealed signiﬁcant reduction
of Dkk2 expression in Sept4−/− HSCs
To investigate themolecular mechanism underlying the accelerated
transdifferentiation of Sept4−/− HSCs [5], we compared the expression
proﬁles of Sept4+/+ and Sept4−/− HSCs cultured in vitro for 3 days
(DIV3). DNA microarray analysis showed that the 2 expression proﬁles
did not show a marked difference, but several genes were expressed
aberrantly in Sept4−/− HSCs (Fig. 1, Tables 2A and 2B, Suppl. Tables 2A,
2B). Among the genes whose differential expression was conﬁrmed by
qRT-PCR (see below), we focused on Dkk2 whose expression was
signiﬁcantly reduced in Sept4−/− HSCs. Dkk2 is a member of the Dkk
gene family (Dkk1–5), each encoding a secretory Wnt antagonist that
interacts with the Wnt–Fzd complex by binding to and internalizing
LRP5/6, a co-receptor of Fzd [10–12]. Previous studies showed that some
Dkks are implicated in the negative regulation of Wnt-mediated cell
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Fig. 1. Comparative genome-wide expression proﬁling between Sept4+/+ and Sept4−/−
hepatic stellate cells. Two-dimensional scatter plot showing comparative transcriptome
data obtained using a DNAmicroarray system (23,474 probes; Mouse Oligo chip, Toray,
Tokyo, Japan). Each dot represents the amount of mRNA obtained from Sept4+/+
hepatic stellate cells (HSCs) (horizontal axis) and Sept4−/− HSCs (vertical axis) on a
log2-based scale. The quality of mRNA and the reproducibility of these experiments are
corroborated by compact clustering of the dots along the diagonal. The results were
conﬁrmed by triplicate measurements. The genes that prominently deviated from the
diagonal are listed in Tables 2A and 2B. This study focused on Dkk2 whose reduced
expression in Sept4−/− HSCs was conﬁrmed by quantitative reverse transcription-
polymerase chain reaction (qRT-PCR) (see below).
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tissues, including the liver [8,9,19].
3.2. Loss of Sept4 suppresses upregulation of Dkk1, 2, 3 in an in vivo
model of hepatitis/ﬁbrosis
We testedwhether the reducedDkk2 expression in cultured Sept4−/−
HSCs is an in vitro artifact or a pathologically relevant recapitulation of a
molecular event during hepatitis and ﬁbrosis. We applied the CCl4 model
of hepatitis/ﬁbrosis to Sept4−/− and Sept4+/+mice as reported previously
[5], andquantiﬁed theexpression levels of 3majorDkkgenes expressed in
the liver by qRT-PCR. While the basal expression levels of Dkk1–3 were
comparable between the 2 genotypes (controls in Fig. 2A–C), their
upregulation after CCl4-induced liver damage was diminished in the
absence of Sept4. Concordantly, the reduction of Dkk2 upregulation in
Sept4−/− liver was observed at the protein level (Fig. 2D). Since Dkks are
responsible for the suppressive modulation of Wnt-mediated inﬂamma-
tory/ﬁbrotic processes [8], their reduction in Sept4−/− liver
may contribute to the enhanced pathological reaction shown previously
[5].
3.3. HSCs are the major source of Dkk1–3 in the liver
To identify the origin of upregulated Dkk1–3 mRNA in vivo, we
fractionated wildtype mouse liver cells into 4 populations (i.e.,
hepatocytes, HSCs, endothelial cells [ECs,] and KCs) and measured
the expression of Dkk1–3 at DIV3 by qRT-PCR. Dkk1–3 were almost
exclusively expressed in HSCs, indicating that HSCs are the major
source of Dkk1–3 secreted in the liver, but hepatocytes and the other
cell types are not (Fig. 3A–C, and data not shown). Concordantly,
immunoblot analysis showed that Dkk2 protein was almost exclu-
sively expressed in HSCs, but not in hepatocytes, ECs, and KCs(Fig. 3D). Since Sept4 is also expressed exclusively in HSCs in the liver
[5], the diminished upregulation of Dkk1–3 is likely to be a cell-
autonomous, if not a direct, consequence of the loss of Sept4.
3.4. Loss of Sept4 suppresses robust upregulation of Dkk2/3 through
myoﬁbroblastic transformation of HSCs in vitro
So far, we have demonstrated that the upregulation ofDkk1–3 is an
HSC-speciﬁc, pathologically relevant event that may antagonize the
inﬂammatory/ﬁbrotic processesmediatedby theWntpathway. To test
whether the 3 major Dkk genes are differentially regulated during
myoﬁbroblastic transformation, we examined the time course of their
expression in HSCs cultured in vitro for 1–5 days by qRT-PCR (Fig. 4).
Consistent with the in vivo results (Fig. 2), Dkk2 and Dkk3 were
remarkably upregulated in this in vitro model, and more impor-
tantly, the upregulation was signiﬁcantly diminished in Sept4−/−
HSCs.
3.5. Dkk2 interferes with the canonical Wnt pathway in human HSC-
derived cells
Because Dkks are secretory proteins that interact with theWnt–Fzd
complex [7,20], it is important to test whether or not Dkks produced by
HSCs can act on HSCs in an autocrine/paracrine manner. Since primary
cultured HSCs are unsuitable for the following assay which requires a
high transfection efﬁciency, we employed a human HSC-derived cell
line, LX-2 [17]. We transfected LX-2 cells either with a FLAG-tagged
mouse Dkk2 expression plasmid or with an empty (FLAG-tag alone)
plasmid, which served as a control. The culture supernatant from each
condition was collected 3 days after transfection, immunoprecipitated
with an anti-FLAG M2 antibody, and immunoblotted for Dkk2. The
immunoblot showed a 28-kDa polypeptide for FLAG-Dkk2 secreted
into the medium (Fig. 5A).
To test whether Dkk2 could interfere with the canonical Wnt
signaling pathway in HSCs, we transfected LX-2 cells with a TOP-Flash
reporter plasmid, which is designed to monitor the activity of the
canonical Wnt pathway through Lef/Tcf-mediated luciferase gene
expression [18]. The reporter-transfected LX-2 cells were supple-
mented with the aforementioned conditioned medium with or
without FLAG-Dkk2. Compared with the control medium, the FLAG-
Dkk2-containing medium signiﬁcantly suppressed the luciferase
activity of LX-2 cells measured 2 days later (Fig. 5B). Taken together,
these data indicate that Dkks secreted from HSCs act on HSCs in an
autocrine/paracrine manner and interfere with the canonical Wnt
pathway, which is known to drive myoﬁbroblastic transformation [9].
However, these data do not exclude the possibility that Dkks suppress
the non-canonical Wnt signaling pathways in HSCs or act on other cell
types in the liver.
3.6. Dkk2 interferes with pro-ﬁbrotic transformation of Sept4−/− HSCs
On the basis of the above results, we examined whether supple-
menting exogenous Dkk2 could mitigate the accelerated ﬁbrotic
transformation of Sept4−/− HSCs. We isolated HSCs from Sept4−/−
mice and cultured them with FLAG-Dkk2-containing or control
medium. After 3 days, we measured the expression of representative
markers by qRT-PCR: the pro-ﬁbrotic genes α-Sma, Col1α1, and Col3α1
(themajor collagen genes in the liver) and an anti-ﬁbrotic gene, Smad7,
which encodes an inhibitor of the transforming growth factor (TGF)-β/
Smad3 pathway. The FLAG-Dkk2-containing medium downregulated
the expression of α-Sma, Col1α1, and Col3α1, and upregulated the
expression of Smad7 in Sept4−/− HSCs (Fig. 6). Concordantly, one-
shot supplementation of recombinant Dkk2 (nominal concentration,
5 μg/ml [184 nM]) gave similar but less signiﬁcant results, partly due to
its low actual potency and/or rapid clearance (Suppl. Fig. 1). These data
indicate that continuous supplementation with Dkk2 can partially
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Fig. 2. Genetic loss of Sept4 affects induced expression patterns of Dkk genes in an in vivomodel of hepatitis and liver ﬁbrosis. (A–C) Quantitative reverse transcription-polymerase chain
reaction (RT-PCR) showed that the basal expression level of the 3 major Dkk genes in the liver, Dkk1–3, were comparable between Sept4+/+ and Sept4−/− hepatic stellate cells (HSCs),
whereas their upregulation upon CCl4-induced liver damage was diminished in the absence of Sept4. The data are shown as mean±SEM (n=6; Dkk1: p=0.35, Dkk2: p=0.037*, Dkk3:
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interfering with the canonical Wnt signaling pathway that transacti-
vates pro-ﬁbrotic genes and suppresses the expression of anti-ﬁbrotic
genes.
3.7. Status of Dkk2 in human HSCs under pathological conditions
We assessed the clinical relevance of our ﬁndings by determining
the status of Dkk2 in pathological human liver specimens using
immunohistochemistry. There was a gradual increment of Dkk2-
immunoreactivity from normal liver tissue, hepatitis, mild ﬁbrosis
through to cirrhosis (Fig. 7A–D). Dkk2-positive cells were detected
almost exclusively in the perisinusoidal spaces where HSCs reside,
and appeared to increase in number as ﬁbrosis progressed. These data
conform to the hypothesis that the upregulation of Dkk2 in HSCs is a
common counteractive mechanism against ﬁbrotic processes in liver
diseases.
4. Discussion
This study derived from an open question raised by our previous
ﬁndings [5], which included the determination of the mechanism that
renders Sept4−/− mice prone to liver ﬁbrosis. Genome-wide expres-sion proﬁling and qRT-PCR analysis revealed that a number of genes in
HSCs are expressed differently in the absence of Sept4. We
hypothesized that these include genes responsible for the ﬁbrosis-
prone phenotype. In this report, we focused on the reduced
expression of the anti-ﬁbrotic genes Dkk1–3 in Sept4−/− HSCs.
Supplementation with recombinant Dkk2 partially corrected the
aberrant gene expression proﬁle in Sept4−/− HSCs by downregulating
the pro-ﬁbrotic genesα-Sma, Col1α1 and Col3α 1 and upregulating the
anti-ﬁbrotic gene Smad7 (Fig. 6, Suppl. Fig. 1). These data indicate that
the scarcity of Dkks is a major, if not the sole, determinant of the
ﬁbrosis-prone phenotype of Sept4−/−mice, partly resolving the initial
question. Other differentially expressed genes include downstream
targets of the canonical Wnt pathway (Suppl. Table 2A and B),
although their contribution has not been assessed in this study.
The molecular network of Wnt signaling consists of 3 major
pathways, i.e., the canonical Wnt/β-catenin pathway, the Wnt/Ca2+
pathway, and the planar cell polarity–convergent extension pathway.
The canonical Wnt pathway plays a critical role in developmental
morphogenesis and homeostatic tissue remodeling by controlling cell
proliferation and differentiation [7,11]. Hence, dysregulation of this
pathway is known to cause cancer [21], aberrant tissue remodeling
[22,23], and ﬁbrosis [6]. This pathway is activated when Wnt binds to
its cognate receptor Fzd, which interacts with the glycogen synthase
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Fig. 7. Dkk2 is upregulated in human hepatic stellate cells under pathological conditions. Immunohistochemistry of Dkk2 in human liver specimens. Dkk2-positive cells (brown
stain) were detected almost exclusively in the perisinusoidal spaces where hepatic stellate cells (HSCs) reside. The level of Dkk2-immunoreactivity appeared to be positively
correlated with the progression of ﬁbrosis from normal liver tissue (A), HCV hepatitis (B), mild ﬁbrosis (C) through to cirrhosis (D). These data conform to the idea that Dkk2
upregulation in HSCs is a common counteractive mechanism against ﬁbrotic processes conserved across species.
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Fig. 8. Sept4 is required to boost the induction of Dkks that counteract myoﬁbroblastic
transformation of hepatic stellate cells. A schematic diagram showing the involvement
of Sept4 in the molecular network underlying the liver ﬁbrosis-prone phenotype of
Sept4−∕− mice. The canonical Wnt pathway promotes myoﬁbroblastic transformation
of HSCs by transactivating pro-ﬁbrotic genes and suppressing anti-ﬁbrotic genes, which
is counteracted by Dkks. This study revealed the involvement of Sept4 as an epistatic
factor that boosts the upregulation of Dkks by unknown mechanism. The missing link
between Sept4 and Dkk induction has become a focus of future studies on the molecular
pathophysiology of liver ﬁbrosis.
1410 A. Yanagida et al. / Biochimica et Biophysica Acta 1812 (2011) 1403–1411expressed in HSCs, Dkk1 consistently antagonizes the canonical Wnt
pathway, while Dkk2 can be either an antagonist or an agonist,
depending on the presence or absence of another Wnt co-receptor,
Kremen1/2 [24]. The expression of Kremen1/2 in HSCs (Suppl. Fig. 2) is
consistent with the antagonistic function of Dkk2 in the canonical
Wnt pathway (Fig. 5). Thus, Dkk1/2 may antagonize the canonical
Wnt pathway in HSCs, though the function of Dkk3 is currently
unclear.
Openquestions also include themolecularmechanism that links loss
of Sept4 and reduced transactivation of the Dkk genes (Fig. 8). Since
Sept4 is a subunit of the septin heteropolymers associated mainly with
other cytoskeletal and submembranous components (see Fig. 1[5]), its
direct interaction with the transcription machinery is unlikely. In some
human cell lines, however, depletion of the Sept7 subunit can release
suppressor of cytokine signaling 7 (SOCS7) from septin heteropolymers
in the cytoplasm,which promotes the translocation of the non-catalytic
region of tyrosine kinase adaptor protein (NCK) to the nucleus and
activates theDNAdamage checkpointmachinery [25]. Thus, genetic loss
of Sept4 could also indirectly alter nuclear events. Another scenario
similar to the scarcity of the dopamine transporter in Sept4−/−
dopamine neurons [3] is that some proteins responsible for anti-ﬁbrotic
signaling could be destabilized by the loss of septin-based scaffolds in
Sept4−/− HSCs. Narrowing down the molecular mechanism from these
and other possibilities should giveus a clearer picture ofmyoﬁbroblastic
transformation of HSCs in liver ﬁbrosis.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbadis.2011.06.015.
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